Crowley Wealth Management Inc. Takes $57,000 Position in Pfizer Inc. (NYSE:PFE)

Crowley Wealth Management Inc. purchased a new stake in shares of Pfizer Inc. (NYSE:PFE) during the fourth quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm purchased 2,151 shares of the biopharmaceutical company’s stock, valued at approximately $57,000.

Other hedge funds have also recently bought and sold shares of the company. Retirement Wealth Solutions LLC acquired a new position in Pfizer during the fourth quarter worth about $26,000. Rialto Wealth Management LLC acquired a new position in Pfizer during the fourth quarter worth about $26,000. Kohmann Bosshard Financial Services LLC acquired a new position in Pfizer during the fourth quarter worth about $28,000. Noble Wealth Management PBC acquired a new position in Pfizer during the fourth quarter worth about $31,000. Finally, Curio Wealth LLC acquired a new position in Pfizer during the fourth quarter worth about $32,000. 68.36% of the stock is owned by institutional investors and hedge funds.

Pfizer Stock Up 0.1 %

Shares of Pfizer stock opened at $26.20 on Monday. The firm has a market cap of $148.61 billion, a price-to-earnings ratio of 18.58, a P/E/G ratio of 0.64 and a beta of 0.61. The company has a debt-to-equity ratio of 0.63, a current ratio of 1.00 and a quick ratio of 0.73. Pfizer Inc. has a 52-week low of $24.48 and a 52-week high of $31.54. The stock has a 50-day simple moving average of $26.17 and a 200-day simple moving average of $27.04.

Pfizer (NYSE:PFE) last announced its quarterly earnings results on Tuesday, February 4th. The biopharmaceutical company reported $0.63 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.48 by $0.15. The business had revenue of $17.76 billion during the quarter, compared to analyst estimates of $17.26 billion. Pfizer had a return on equity of 19.47% and a net margin of 12.62%. The firm’s revenue was up 24.7% on a year-over-year basis. During the same period in the previous year, the company earned $0.10 EPS. On average, equities research analysts expect that Pfizer Inc. will post 2.95 earnings per share for the current fiscal year.

Insider Activity

In other news, Director Ronald E. Blaylock purchased 19,457 shares of Pfizer stock in a transaction dated Thursday, February 13th. The stock was acquired at an average cost of $25.65 per share, for a total transaction of $499,072.05. Following the acquisition, the director now directly owns 27,707 shares in the company, valued at $710,684.55. This represents a 235.84 % increase in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which can be accessed through the SEC website. 0.06% of the stock is owned by corporate insiders.

Analysts Set New Price Targets

A number of research analysts recently issued reports on the company. Truist Financial lowered their target price on Pfizer from $36.00 to $32.00 and set a “buy” rating on the stock in a report on Wednesday, December 18th. UBS Group decreased their price target on Pfizer from $31.00 to $29.00 and set a “neutral” rating for the company in a research report on Wednesday, January 8th. Citigroup decreased their price target on Pfizer from $30.00 to $29.00 and set a “neutral” rating for the company in a research report on Tuesday, January 28th. Bank of America reiterated a “neutral” rating and issued a $29.00 price target on shares of Pfizer in a research report on Tuesday, December 10th. Finally, Guggenheim reiterated a “buy” rating on shares of Pfizer in a research report on Tuesday, March 18th. One research analyst has rated the stock with a sell rating, seven have assigned a hold rating, six have issued a buy rating and three have issued a strong buy rating to the company’s stock. According to MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and an average target price of $31.92.

Pfizer Profile

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.